Amgen, AstraZeneca's tezepelumab hits goal in asthma phase 3

Amgen, AstraZeneca's tezepelumab hits goal in asthma phase 3

Source: 
Fierce Pharma
snippet: 

A phase 3 trial of Amgen and AstraZeneca’s tezepelumab in severe asthma patients has met its primary endpoint. The thymic stromal lymphopoietin inhibitor drove reductions in exacerbations in patients with low levels of eosinophils, teeing the partners up to target a large, underserved portion of the asthma market.